ClinicalTrials.gg
CompletedNCT02795182Updated Jul 1, 2022Results posted

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

A Phase 1 interventional study of Zanubrutinib and Tislelizumab in Lymphoma and Leukemia, sponsored by BeiGene. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-01.

Sponsored by BeiGene · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 120 studies in Lymphoma with a site in Australia — 24 open to participants now, 40 under way, 15 of them phase 3. Lymphoma · Australia.

Enrollment
83rd of 116
75 · median 132
Started
2016
with 1 other
Phase 1
24 of 120
6 open now
Registered
64th of 120
by date

Among the 120 studies in Lymphoma with a site in Australia, this one is the 83rd largest by enrollment of the 116 interventional ones that give a count, is one of 2 that started in 2016, is one of 24 in phase 1, and was the 64th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

24 of the 120 studies in Lymphoma with a site in Australia are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Lymphoma with a site in Australia, or all of them as a file.
02

Study summary

This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with BGB-A317 in participants with B-cell lymphoid malignancies.

03

Conditions studied

  • Lymphoma
  • Leukemia

Keywords

  • Relapsed
  • Refractory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

Participants may be entered in the study only if they meet all of the following criteria:

  1. Dose escalation for Dose Levels 1, 2, and 3: participants with World Health Organization (WHO) classification-defined B-lymphoid following at least 1 , with no therapy of higher priority available, including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), human cultured lymphoblast (HCL), Marginal zone lymphoma (MZL), non-germinal center B-cell (GCB) DLBCL, GCB DLBCL, transformed FL, and Richter's transformation (NOTE: participants with WM are excluded from enrollment as of Amendment 3).
  2. Dose expansion for Cohorts 1 to 4: participants with either of the following relapsed or refractory WHO-classified lymphoid malignancies who have received at least 1 prior line of standard therapy: a. Cohort 1: GCB DLBCL, with cell of origin defined by either immunohistochemistry or gene expression profiling. b. Cohort 2: non-GCB DLBCL, with cell of origin defined by either immunohistochemistry or gene expression profiling. participants who have transformed to DLBCL from another histology may be enrolled into Cohort 3. c. Cohort 3: Transformed lymphoid malignancy, including but not limited to: i. Large cell transformation of chronic lymphocytic leukemia (Richter's transformation). ii. Large cell transformation of other WHO-classified indolent non-Hodgkin's lymphoma, including FL, or MZL. d. Cohort 4: confirmed primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL) of breast or testicular origin: i. Must be able to tolerate lumbar puncture and/or Ommaya taps. ii. Must have received at least 1 prior central nervous system (CNS)-directed therapy. iii. Presence of brain parenchymal and/or .
  3. Aged ≥ 18 years, able and willing to provide written and to comply with the study protocol.
  4. for non-Hodgkin lymphoma defined as ≥ 1 nodal lesion that is > 15 mm in the longest diameter and can be accurately measured in at least 2 dimensions with computed tomography (CT) scan, or ≥ 1 extra-nodal lesion that is > 10 mm in the longest diameter and can be accurately measured in at least 2 dimensions with CT scan, except for PCNSL or SCNSL.
  5. Participants with an accessible tumor lesion must agree to a tumor at screening and another before the drug administration on Cycle 1 Day 8, ideally taken from the same tumor lesion, for biomarker analysis (up to first 12 qualified participants), except for PCNSL. Additionally, participants with DLBCL must have archival tumor tissue or agree to a tumor biopsy for confirmation of the DLBCL subtype.
  6. Laboratory parameters as specified below: a. Hematologic: count ≥ 50 × 109/L; ≥ 1.0 × 109 cells/L; participants with neutrophils \< 1.0 × 109/L unless cytopenias are a direct result of active leukemia or lymphoma, in which case platelet count ≥ 35 × 109/L, absolute neutrophil count ≥ 0.75 × 109/L are allowed. (Note: Platelet transfusion administered ≤ 7 days of screening to raise pre-treatment platelet count to ≥ 35 x 109/L is prohibited.) b. Hepatic: Total ≤ 1.5 the (ULN) or ≤ 2.0 × ULN for participants with Gilbert syndrome, (AST), and alanine aminotransaminase (ALT) ≤ 3 × ULN. c. Renal: ≥ 30 mL/min (as estimated by the Cockcroft-Gault equation or as measured by nuclear medicine scan or 24-hour urine collection). participants requiring hemodialysis will be excluded.
  7. Anticipated survival of at least 4 months.
  8. (ECOG) performance status of 0 to 2.
  9. Female participants of and nonsterile males must practice at least 1 of the following methods of with partner(s) throughout the study and for ≥ 3 months after discontinuing study drug: total abstinence from sexual intercourse, double-barrier contraception, intrauterine device or hormonal contraceptive initiated at least 3 months prior to first dose of study drug.
  10. Male participants must not donate sperm from initial study drug administration until 180 days after drug discontinuation.

Key Exclusion Criteria

Participants will not be entered in the study for any of the following reasons:

  1. Known, active, CNS lymphoma or leukemia, except for Cohorts 4.
  2. Diagnosis with Waldenstrom's macroglobulinemia (WM).
  3. For PCNSL and SCNSL (Cohorts 4): a. Require therapy > 16 mg dexamethasone daily or equivalent. b. Corticosteroid therapy ≤ 16 mg dexamethasone daily or equivalent at study entry from which, in the Investigator's opinion, it is expected that the participant cannot be tapered off after the first 4 weeks of study treatment. c. Intraocular PCNSL without evidence of brain disease. d. SCNSL actively receiving treatment for extra-CNS disease. e. PCNSL actively receiving concomitant local or systemic therapy for CNS disease.
  4. Uncontrolled hemolytic anemia or idiopathic thrombocytopenia purpura.
  5. History of stroke or cerebral hemorrhage within 6 months of enrollment.
  6. History of significant cardiovascular disease, defined as: a. Congestive heart failure greater than (NYHA) class II according to the NYHA functional classification. b. Unstable angina or myocardial infarction with 6 months of enrollment. c. Serious cardiac arrhythmia or abnormality: wave (QTcF) > 480 msec based on the Fridericia's formula or other ECG abnormalities including second-degree atrioventricular block type II, third-degree atrioventricular block. Participants who have a pacemaker will be allowed on study despite ECG abnormalities or the inability to calculate the QTc.
  7. Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of breath, congestive obstructive pulmonary disease).
  8. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy.
  9. Prior Bruton's tyrosine kinase (BTK) inhibitor or /anti-PD-L1 treatment.
  10. Any illness or condition that in the opinion of the investigator may affect safety of treatment or evaluation of any study endpoint.
  11. Active autoimmune diseases or history of severe autoimmune diseases; these include but are not limited to a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis systemic lupus erythematosus, rheumatoid arthritis, connective tissue diseases, scleroderma, inflammatory bowel disease, Crohn's disease, ulcerative colitis, autoimmune hepatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, or clinically manifest antiphospholipid syndrome. Note: Participants are permitted to enroll if they have vitiligo, eczema, type I diabetes mellitus, or endocrine deficiencies, including thyroiditis managed with replacement hormones including physiologic doses of corticosteroids. Participants with Sjögren's syndrome and psoriasis controlled with topical medication and participants with positive serology, such as antinuclear antibodies or antithyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible.
  12. A condition requiring systemic treatment with either corticosteroids (> 20 mg daily prednisone or equivalent) or other medications within 14 days of study drug administration, except for PCNSL and SCNSL. Note: adrenal replacement doses ≤ 20 mg daily prednisone or equivalents are permitted in the absence of active autoimmune disease; Participants are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption).
  13. History of interstitial lung disease or noninfectious pneumonitis, except for those induced by radiation therapy.
  14. Requirement for medications which strong cytochrome P450 (CYP)3A inhibitors or inducers.
  15. Vaccination with a within 28 days of the initiation of treatment.
  16. A candidate for hematopoietic stem cell transplantation. Participants are excluded if they had received an stem cell transplantation within 6 months or have active graft-versus-host-disease requiring ongoing immunosuppression.
  17. Participated in any drug study within 28 days or not recovered from toxicity of any prior chemotherapy to Grade ≤ 1.
  18. History of other active malignancies within 2 years of study entry, with the exception of adequately treated in-situ carcinoma of cervix; localized basal cell or squamous cell carcinoma of skin; or previous malignancy confined and treated locally (surgery or other modality) with curative intent.
  19. Major surgery in the past 4 weeks prior to the first day of screening.
  20. Active and symptomatic fungal, bacterial, and/or viral infection; human T-cell lymphotropic virus type 1 seropositive status.
  21. (HIV) infection, or active (e.g., hepatitis B surface antigen [HBsAg] reactive) or (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] detected. • Hepatitis B/C serologic markers and viral load will be tested at screening. The hepatitis B testing includes HBsAg, HBcAb, and HBsAb as well as hepatitis B virus (HBV) DNA by Polymerase chain reaction (PCR) if the participant is negative for HBsAg but HBcAb positive (regardless of HBsAb status). The hepatitis C testing includes Hepatitis C virus (HCV) antibody as well as HCV RNA by PCR if the Participant is HCV antibody positive. Participants with positive HBsAg and/or detectable level of HBV DNA or detectable level of HCV RNA (≥ 15 IU/mL) are not eligible. Participants negative for HBsAg, HBcAb positive, and HBV DNA negative must undergo monthly HBV DNA screening by PCR. Participants positive for HCV antibody but negative for HCV RNA (defined as \< 15 IU) must undergo monthly HCV RNA screening.
  22. Inability to comply with study procedures.
  23. Pregnant or nursing women.
  24. Men or women of childbearing potential who refuse to use an adequate measure of contraception, unless they have past medical history of surgical sterilization.
  25. Currently taking or plan to take CNS penetrant therapy such as thiotepa, cytarabine, or partially CNS penetrant agents known to be active in lymphoid tumors, such as rituximab.
  26. Has taken or plans to take any chemotherapy, immunotherapy (eg, interleukin, interferon, thymoxin), or any investigational therapies to treat leukemia or lymphoma within 28 days or 5 half-lives (whichever is shorter) of the first study drug administration, including CNS penetrating agents.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Other
    Zanubrutinib abd Tislelizumab

    Based on results of the dose escalation cohorts and the identified recommended Phase 2 dose, all patients will receive zanubrutinib at 160 mg orally twice daily in combination with intravenous infusion of tislelizumab 200mg given every 21 days, to be continued until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination

    Drug: Zanubrutinib · Drug: Tislelizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Maximum Tolerated Dose (MTD) of Tislelizumab

    The MTD of tislelizumab is considered the dose level below that at which at least 2 participants (or at least 33%) experience a dose-limiting toxicity (DLT).

    Time frame: From the date of first dose of study drugs until RP2D was determined (Approximately 1 year and 10 months)

  2. Dose Escalation: RP2D of Tislelizumab

    The RP2D of tislelizumab in combination with zanubrutinib will be selected by taking into account the safety, tolerability, and pharmacokinetic (PK) profile.

    Time frame: From the date of first dose of study drugs until final R2PD was decided (Approximately 1 year and 10 months)

Secondary outcomes

  1. Number of Participants With TEAEs and SAEs

    A treatment-emergent adverse event (TEAE) was defined as an AE that had an onset date during the treatment emergent period, defined as from the first dose date of zanubrutinib or tislelizumab (whichever is earlier) through 30 days after the last dose (permanent discontinuation of study drug) of zanubrutinib or 90 days after the last dose of tislelizumab, whichever is later, or prior to initiation of new anti-cancer therapy. Treatment-related serious adverse events (SAEs) and any worsening of a TEAE by PT post treatment-emergent period were also counted as TEAEs.

    Time frame: From the day of first dose of study drug until end of study (up to 4 years and 6 months)

  2. Overall Response Rate

    ORR, is defined as the percentage of participants who had complete response (CR) or partial response (PR) by standard disease-specific response criteria. for WM participants ORR includes minor response (MR) and very good partial response (VGPR).

    Time frame: Up to 4 years and 6 months

  3. Duration of Response (DOR)

    DOR is defined as the time from the date that a confirmed objective response is first documented to the date of progressive disease (PD) or death due to any cause for those participants with a confirmed PR or CR.

    Time frame: Up to 4 years and 6 months

  4. Progression Free Survival (PFS)

    PFS, is defined as the time from the first dose of study medication to objective disease progression or death

    Time frame: Up to 4 years and 6 months

  5. Number of Participants With Anti-Drug Antibodies (ADAs) to Tislelizumab

    Time frame: From the day of first dose of study drug until end of study (up to 4 years and 6 months)

07

Results

Posted Jul 1, 2022

Participant flow

The study consisted of a dose escalation phase during which 3 dose levels of tislelizumab were administered in combination with a total of 320 mg zanubrutinib to determine the recommended phase 2 dose (RP2D). Once RP2D was determined all participants remaining in the study were switched to RP2D. A total of 75 participants were enrolled in both phases combined. As pre-specified in the protocol, analyses were conducted by disease subtype on the overall enrolled participants and not by phases.

Participant flow — Overall Study
MilestoneDose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg Q3WDose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg Q3WDose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3WDose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W
Started1510743
Completed0000
Not completed1510743
Withdrew: Death54418
Withdrew: Sponsor's decision at discontinuation and death at end of trial0001
Withdrew: Physician's decision at discontinuation and death at end of trial0002
Withdrew: Study ended by sponsor once primary and secondary objectives were met3208
Withdrew: Withdrawal by subject4003
Withdrew: Lost to follow-up0011
Withdrew: Roll over to long term extension3325
Withdrew: Progressive disease0104
Withdrew: Physician decision0001

Outcome measures

PrimaryDose Escalation: Maximum Tolerated Dose (MTD) of Tislelizumab

The MTD of tislelizumab is considered the dose level below that at which at least 2 participants (or at least 33%) experience a dose-limiting toxicity (DLT).

Time frame:
From the date of first dose of study drugs until RP2D was determined (Approximately 1 year and 10 months)
Reported as:
Number · mg
Dose Escalation: Maximum Tolerated Dose (MTD) of Tislelizumab
mgDose Escalation Phase
Dose Escalation: Maximum Tolerated Dose (MTD) of TislelizumabNA
PrimaryDose Escalation: RP2D of Tislelizumab

The RP2D of tislelizumab in combination with zanubrutinib will be selected by taking into account the safety, tolerability, and pharmacokinetic (PK) profile.

Time frame:
From the date of first dose of study drugs until final R2PD was decided (Approximately 1 year and 10 months)
Reported as:
Number · mg
Dose Escalation: RP2D of Tislelizumab
mgDose Escalation Phase
Dose Escalation: RP2D of Tislelizumab200
SecondaryNumber of Participants With TEAEs and SAEs

A treatment-emergent adverse event (TEAE) was defined as an AE that had an onset date during the treatment emergent period, defined as from the first dose date of zanubrutinib or tislelizumab (whichever is earlier) through 30 days after the last dose (permanent discontinuation of study drug) of zanubrutinib or 90 days after the last dose of tislelizumab, whichever is later, or prior to initiation of new anti-cancer therapy. Treatment-related serious adverse events (SAEs) and any worsening of a TEAE by PT post treatment-emergent period were also counted as TEAEs.

Time frame:
From the day of first dose of study drug until end of study (up to 4 years and 6 months)
Reported as:
Number · Number of participants
Number of Participants With TEAEs and SAEs
Number of participantsDose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg Q3WDose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg Q3WDose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3WDose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W
Participants With at Least One TEAE159740
Participants With at Least One SAE1010423
SecondaryOverall Response Rate

ORR, is defined as the percentage of participants who had complete response (CR) or partial response (PR) by standard disease-specific response criteria. for WM participants ORR includes minor response (MR) and very good partial response (VGPR).

Time frame:
Up to 4 years and 6 months
Reported as:
Number · Percentage of participants
Overall Response Rate
Percentage of participantsOther B-Cell MalignanciesGCB DLBCLNon-GCB DLBCLRichter's TransformationTransformed Lymphoid MalignancyPCNSL or SCNSL of Breast or Testicular Origin
Overall Response Rate37.5 (15.2 to 64.6)25.0 (5.5 to 57.2)40.0 (16.3 to 67.7)42.9 (9.9 to 81.6)40 (19.1 to 63.9)40 (5.3 to 85.3)
SecondaryDuration of Response (DOR)

DOR is defined as the time from the date that a confirmed objective response is first documented to the date of progressive disease (PD) or death due to any cause for those participants with a confirmed PR or CR.

Time frame:
Up to 4 years and 6 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsOther B-Cell MalignanciesGCB DLBCLNon-GCB DLBCLRichter's TransformationTransformed Lymphoid MalignancyPCNSL or SCNSL of Breast or Testicular Origin
Duration of Response (DOR)22.36 (7.72 to NA)NA (NA to NA)6.79 (2.36 to NA)17.47 (2.96 to NA)8.89 (2.83 to NA)7.80 (7.06 to 8.55)
SecondaryProgression Free Survival (PFS)

PFS, is defined as the time from the first dose of study medication to objective disease progression or death

Time frame:
Up to 4 years and 6 months
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsOther B-Cell MalignanciesGCB DLBCLNon-GCB DLBCLRichter's TransformationTransformed Lymphoid MalignancyPCNSL or SCNSL of Breast or Testicular Origin
Progression Free Survival (PFS)16.94 (5.39 to NA)1.43 (0.57 to NA)2.80 (1.43 to 6.99)2.93 (2.43 to 20.33)4.68 (1.26 to 8.52)8.42 (0.33 to 16.07)
SecondaryNumber of Participants With Anti-Drug Antibodies (ADAs) to Tislelizumab
Time frame:
From the day of first dose of study drug until end of study (up to 4 years and 6 months)
Reported as:
Number · Number of participants
Number of Participants With Anti-Drug Antibodies (ADAs) to Tislelizumab
Number of participantsDose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg Q3WDose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg Q3WDose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3WDose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W
Treatment Emergent ADA0001
Neutralizing antibody Positive0000

Adverse events

Collected over From the Day of first dose of study drug until end of Study (up to 4 years and 6 months). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg5/15 (33.3%)10/15 (66.7%)15/15 (100%)
Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg4/10 (40%)10/10 (100%)9/10 (90%)
Dose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W4/7 (57.1%)4/7 (57.1%)7/7 (100%)
Dose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W21/43 (48.8%)23/43 (53.5%)40/43 (93%)
Most frequent serious events
Showing 10 of 71
Most frequent serious events
EventDose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kgDose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kgDose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3WDose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W
PyrexiaGeneral disorders0/152/100/70/43
PneumoniaInfections and infestations1/152/100/71/43
Haemolytic transfusion reactionInjury, poisoning and procedural complications0/152/100/70/43
Immune-mediated enterocolitisGastrointestinal disorders0/151/101/71/43
Drug hypersensitivityImmune system disorders0/150/101/70/43
SepsisInfections and infestations0/150/101/70/43
HypercalcaemiaMetabolism and nutrition disorders0/150/101/70/43
AnaemiaBlood and lymphatic system disorders0/151/100/71/43
Atypical haemolytic uraemic syndromeBlood and lymphatic system disorders0/151/100/70/43
Multiple organ dysfunction syndromeGeneral disorders0/151/100/72/43
Most frequent other events
Showing 10 of 179
Most frequent other events
EventDose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kgDose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kgDose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3WDose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W
DiarrhoeaGastrointestinal disorders6/152/102/710/43
FatigueGeneral disorders5/152/100/79/43
Upper respiratory tract infectionInfections and infestations5/153/101/75/43
NauseaGastrointestinal disorders4/153/101/77/43
HeadacheNervous system disorders1/153/100/74/43
CoughRespiratory, thoracic and mediastinal disorders4/153/100/77/43
Urinary tract infectionInfections and infestations1/150/102/76/43
RashSkin and subcutaneous tissue disorders2/151/102/73/43
ContusionInjury, poisoning and procedural complications2/152/100/710/43
AnaemiaBlood and lymphatic system disorders2/151/100/79/43

Baseline characteristics

Safety analysis set includes all participants who receive at least 1 dose of zanubrutinib and/or tislelizumab.

Age, Continuous
Age, Continuous(years)Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg Q3WDose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg Q3WDose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3WDose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3WTotal
Mean60.4 ± 12.6360.7 ± 6.5270.4 ± 5.2666.7 ± 9.8565.0 ± 10.20
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg Q3WDose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg Q3WDose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3WDose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3WTotal
Female4541629
Male11532746
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg Q3WDose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg Q3WDose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3WDose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3WTotal
Hispanic or Latino00011
Not Hispanic or Latino12773864
Unknown or Not Reported330410
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg Q3WDose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg Q3WDose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3WDose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3WTotal
Race- White14973363
Race - Asian110911
Race - Other00011
08

Study locations

10 sites
  • St Vincent's Hospital
    Darlinghurst, New South Wales, Australia
  • Concord Hospital
    Sydney, New South Wales 2139, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania, Australia
  • Monash Hospital
    Clayton, Victoria 3168, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3002, Australia
  • Epworth Healthcare
    Richmond, Victoria, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Guangdong General Hospital
    Guangzhou, Guangdong, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
  • Shanghai jiaotong university school of medicine Ruijin Hospital
    Shanghai, Shanghai 200025, China
09

References and documents

Publications

  • Othman J, Verner E, Tam CS, Huang J, Lin L, Hilger J, Trotman J, Gasiorowski R. Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenstrom macroglobulinemia. Haematologica. 2018 May;103(5):e223-e225. doi: 10.3324/haematol.2017.186817. Epub 2018 Feb 8. No abstract available. PubMed 29439186 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Dec 2020, 53 months.

Results were first posted in Jul 2022, 1 year 6 months after primary completion.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 53 months is above that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2016
First posted
Jun 10, 2016
StartActual
Jun 29, 2016
Primary completionActual
Dec 18, 2020
CompletionActual
Dec 18, 2020
Results first posted
Jul 1, 2022
Last update
Jul 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02795182
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jun 10, 2016
Start date
Jun 29, 2016
Primary completion
Dec 18, 2020
Completion
Dec 18, 2020
Results posted
Jul 1, 2022
Last update
Jul 1, 2022

Study contacts

Study Director
principal investigator · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zanubrutinib · Tislelizumab

Start the discussion